Table 4 Some important clinical trials about the applications of nanorobots or nanomedicine on cancer treatments
From: Advances of medical nanorobots for future cancer treatments
Study | NCT number | Title | Status | Clinical trial outcome | Conditions | Interventions | Outcome measures | Gender | Age | Phases | Enrollment | Study type | Study designs | Start date | Primary completion date | Completion date | Country |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04918381 | CellFX Treat & Resect Low-Risk BCC Feasibility Study | Completed | The study included 30 participants with a total of 37 BCC lesions. The primary purpose of the study was treatment, and there was no control group. This study found that the CellFX system was safe and feasible for the treatment of low-risk BCC lesions, with no serious adverse events reported. The trial was sponsored by Pulse Biosciences, Inc. and was completed in 2022 | BCC—Basal cell carcinoma BCC excision margin | Device: CellFX system | Number of lesions with BCC histological clearance; number of participants with treatment related serious adverse events | All | 22–85 years (Adult, older adult) | Not applicable | 30 | Interventional | Allocation: N/A; intervention model: single group assignment; masking: none (open label); primary purpose: treatment; | 02-Jun-21 | 02-Mar-22 | 22-Jul-22 | United States |
2 | NCT04789486 | Nano-SMART: nanoparticles with MR guided SBRT in centrally located lung tumors and pancreatic cancer | Recruiting | No final result was reported yet | Non-small cell lung cancer, advanced pancreatic adenocarcinoma, unresectable pancreatic cancer, ductal adenocarcinoma of the pancreas | Drug: AGuIX, radiation: radiotherapy | Maximum tolerated dose (MTD), Phase 1, compare local control at month 12th of maximum tolerated dose MTD—Phase 2, progression-free survival (PFS) at maximum tolerated dose (MTD), overall response rate (ORR) at maximum tolerated dose (MTD), serious adverse events at day 90th, serious adverse events at month 12th, tumor changes, compare disease-specific survival, compare R0 resection rate, compare overall survival, quality of life (QoL)-performance status utilizing PROMIS physical and mental health batteries, quality of life (QoL)-completion of daily activities utilizing PROMIS physical and mental health batteries | All | 18 years old and older (adult, older adult) | Phase 1, Phase 2 | 100 | Interventional | allocation: randomized, intervention model: parallel assignment, masking: none (open label), primary purpose: treatment | 27-May-21 | 10-Apr-23 | 10-Sep-24 | United States |
3 | NCT05340725 | Rectal dexmedetomidine niosomes for postoperative analgesia in pediatric cancer patients | Recruiting | No final result was reported yet | Postoperative pain | Drug: DEX-IV; drug: DEX-Rectal; drug: DEX-Nano-Rectal | Serum concentrations of Dexmedetomidine, postoperative FLACC pain score | All | 3–7 years old (children) | Phase 2, Phase 3 | 45 | Interventional | Allocation: randomized, intervention model: parallel assignment, masking: quadruple (participant, care provider, investigator, outcomes assessor, primary purpose: treatment | 1-May-22 | 1-Dec-23 | 1-Dec-23 | Egypt |
4 | NCT04759820 | Carbon nanoparticles vs indocyanine green | Recruiting | No final result was reported yet | Number of lymph node retrieved | Drug: carbon nanoparticles suspension, drug: indocyanine green | Number of lymph nodes detected; number of positive lymph nodes detected at different T stages, the ratio of positive lymph nodes, patients’ disease-free survival (DFS) | All | 18–70 years old (adult, older adult) | Phase 2, Phase 3 | 298 | Interventional | Allocation: randomized, intervention model: parallel assignment, masking: none (open label), primary purpose: prevention | 1-Jan-21 | 30-Jun-22 | 30-Jun-23 | China |
5 | NCT04881032 | AGuIX nanoparticles with radiotherapy plus concomitant temozolomide in the treatment of newly diagnosed glioblastoma | Recruiting | No final result was reported yet |  | Drug: polysiloxane Gd-chelates-based nanoparticles (AGuIX), radiation: radiotherapy, drug: Temozolomide | The recommended dose (phase I) of AGuIX in combination with TMZ and radiotherapy during the radio-chemotherapy period, 6-month progression-free survival (PFS) rate (phase II), pharmacokinetic Cmax of AGuIX, pharmacokinetic Tmax of AGuIX, pharmacokinetic AUC of AGuIX, pharmacokinetic t1/2 of AGuIX, distribution of AGuIX, overall survival, progression-free survival (PFS), toxicity (CTCAE criteria) | All | 18–75 years old (adult, older adult) | Phase 1, Phase 2 | 66 | Interventional | Allocation: randomized, intervention model: parallel assignment, masking: none (open label), primary purpose: treatment | 7-Mar-22 | Sep-24 | Mar-26 | France |